Why the study?
Does transcatheter mitral valve-in-valve using the SAPIEN 3 transcatheter heart valve improve outcomes in patients with failed surgical bioprosthetic valves?
Does transcatheter mitral valve-in-valve using the SAPIEN 3 transcatheter heart valve improve outcomes in patients with failed surgical bioprosthetic valves?
Transseptal mitral valve-in-valve using the SAPIEN 3 valve is a viable option with high success and low mortality at 1 year for patients with failed surgical bioprostheses.
Answers are grounded in this paper and cite their sources.
May support MViV with SAPIEN 3 for failed bioprostheses; extends observational data but leaves open need for RCTs.
Transcatheter MViV using the SAPIEN 3 transcatheter heart valve is associated with high technical success, low 30-day and 1-year mortality, significant improvement of heart failure symptoms, and sustained valve performance. Transseptal MViV should be considered an option for most patients with failed surgical bioprosthetic valves and favorable anatomy.
No takes yet. Share an insight, caveat, or question.
Whisenant et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: